Study guide
10.3 Antigen-Antibody Interactions and Testing
Scientist in Blood Banking, BB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes and Application 1.3 CMP, Credential Citation, and BB vs SBB
2 Donors and Collection
2.1 Donor Qualification 2.2 Collection Methods and Adverse Reactions 2.3 Special Donations
3 Processing, Storage, and Component QC
3.1 Processing: FDA/AABB Requirements, Testing, and Labeling 3.2 Anticoagulants, Additives, and Storage Temperatures 3.3 Transportation, Stored-Product Properties, and Expiration 3.4 Blood Component Quality Control
4 Blood Components
4.1 Red Blood Cells, Whole Blood, Washed, Frozen, and Rejuvenated 4.2 Platelets, Plasma, and Cryoprecipitated AHF 4.3 Granulocytes, Leukoreduced, and Irradiated Components 4.4 Apheresis Products, Fractionation, and Hematopoietic Progenitors
5 Blood Group Genetics and Transfusion Role
5.1 Basic and Molecular Genetics 5.2 Inheritance of Blood Groups 5.3 Immunogenicity and Antigen Prevalence
6 ABO and Lewis Systems
6.1 ABO Biochemistry and Antigens 6.2 ABO Antibodies, Discrepancies, and Subgroups 6.3 Lewis System
7 Rh System
7.1 Rh Genetics and Antigens 7.2 Weak D, Partial D, and Rh Antibodies 7.3 Rh Phenotyping and Clinical Significance
8 Kell, Duffy, Kidd, and MNS
8.1 Kell System 8.2 Duffy System 8.3 Kidd System 8.4 MNS System
9 Additional Systems and Antigens
9.1 P1PK, Globoside, and Ii Systems 9.2 Lutheran and Other Blood Group Systems 9.3 High- and Low-Prevalence Antigens 9.4 HLA, Platelet-Specific, and Granulocyte-Specific Antigens
10 Immunology Foundations
10.1 Immune Response, B and T Cells, Macrophages 10.2 Immunoglobulins: Classes, Structure, and Properties 10.3 Antigen-Antibody Interactions and Testing 10.4 Complement Pathways and Biologic Properties
11 Physiology, Hemostasis, Cytopenias, and Transplantation
11.1 Physiology of Blood 11.2 Hemostasis and Coagulation 11.3 Immune and Nonimmune Cytopenias 11.4 Solid Organ and HPC Transplantation
12 Hemolytic Disease of the Fetus and Newborn
12.1 HDFN Pathophysiology 12.2 HDFN Detection 12.3 HDFN Treatment and Prevention
13 Routine Serologic Testing
13.1 Blood Grouping Tests 13.2 Antibody Detection 13.3 Compatibility Testing and Crossmatch 13.4 Direct Antiglobulin Testing
14 Antibody Identification
14.1 Antibody Identification and Rule-Out 14.2 Clinical Significance, Dosage, and Multiple Antibodies 14.3 Panel Problem-Solving and Common Traps
15 Reagents and Special Techniques
15.1 Antiglobulin Sera, Grouping Sera, and Reagent Red Cells 15.2 Enzymes, Enhancement Media, and Lectins 15.3 Adsorption, Elution, Titration, and Cell Separations 15.4 Molecular, Solid-Phase, Column, ELISA, and Related Methods
16 Serologic QA and Special Reagents
16.1 Blood Sample Quality Assurance 16.2 Reagent and Procedure Quality Assurance 16.3 Thiol Reagents, Neutralization, Chloroquine, EGA, and Immunofluorescence
17 Indications and Component Therapy
17.1 Indications for Transfusion 17.2 Red Cell and Whole Blood Therapy 17.3 Platelet, Plasma, and Cryoprecipitate Therapy 17.4 Special Component Therapy
18 Adverse Effects of Transfusion
18.1 Immunologic Transfusion Reactions 18.2 Nonimmunologic Transfusion Reactions 18.3 Transfusion-Transmitted Diseases
19 Apheresis, Administration, and Patient Blood Management
19.1 Apheresis and Extracorporeal Circulation 19.2 Blood Administration 19.3 Patient Blood Management
20 Laboratory Operations
20.1 Quality Assessment and Troubleshooting 20.2 Quality Control, Proficiency Testing, and Regulation 20.3 Laboratory Safety 20.4 Laboratory Mathematics and Instrumentation
10.3 Antigen-Antibody Interactions and Testing
Key Takeaways Explain This Topic AI
Affinity is one Fab–epitope bond; avidity is the summed strength of every bond, which is why pentameric IgM can react strongly even when per-site affinity is modest.
Visible agglutination is a lattice at the zone of equivalence; prozone is antibody excess and a false negative until the serum is diluted.
Zeta potential holds red cells about 25 nm apart: IgM can span that gap in saline, IgG cannot, so AHG must bridge Fc.
LISS speeds uptake, PEG concentrates antibody, enzymes drop zeta and destroy selected antigens, and albumin is the older zeta reducer — recipes come later.
DAT detects in-vivo coating and IAT detects in-vitro coating; hemolysis is a positive result, temperature splits cold IgM from warm IgG, and dosage can hide Kidd on a heterozygous cell.
Last updated: August 2026
10.3 Antigen-Antibody Interactions and Testing
Quick Answer: Affinity is one Fab–epitope bond; avidity is the sum of all bonds (IgM wins on avidity). Visible agglutination needs a lattice at the zone of equivalence . Prozone is antibody excess and a false negative until you dilute. Zeta potential (~25 nm gap from sialic acid) lets IgM agglutinate in saline and stops IgG until AHG bridges. LISS speeds uptake; PEG concentrates antibody; enzymes cut sialic acid and destroy some antigens; albumin is the older zeta reducer. DAT = in-vivo coating; IAT = in-vitro coating. Hemolysis is a positive result . Cold IgM versus warm IgG is the first ID clue. Dosage is a stronger reaction with homozygous antigen.
The June 9, 2026 BB outline puts antigen–antibody interactions at III.A.3 . This section is the physics. Tube versus gel recipes, adsorption, and elution live later (Chapters 13–16). Learn why the media work so those methods pages are not a memorized cookbook.
Affinity, avidity, lattice, zones
Affinity is the intrinsic strength of one binding site for one epitope. Avidity is the functional strength of the whole molecule. IgM may have modest affinity per Fab and still win on avidity because ten sites grab at once.
Red cells and antibody form a visible lattice only when both sides are multivalent and the ratio is right — the zone of equivalence .
Prozone: antibody excess. Every epitope is saturated by a separate IgG, so cells cannot be cross-linked. The undiluted tube looks negative; a dilution (or a titration) unmasks agglutination. High-titer anti-D and some cold agglutinins do this.
Postzone: antigen excess. Not enough antibody to link a sea of red cells. Weak antibodies plus a heavy cell suspension create postzone.
Never call a negative “no antibody” until the method has left prozone and the cell dose is not ridiculous.
Zeta potential is why IgM works in saline and IgG does not
Red-cell membranes are coated with sialic acid . The net negative charge, plus the ionic cloud, creates zeta potential — cells remain about 25 nm apart.
IgM is large enough (~30 nm span) to bridge that gap → saline agglutinin , immediate-spin visible.
IgG spans only about 14 nm → no saline agglutination → incomplete antibody → AHG (or a potent enhancer) must close the gap.
That is the entire reason the AHG phase exists. Column agglutination and solid-phase methods still detect IgG coating; they just use a different geometry than a tube lattice. The principle does not change: IgG is on the cell, and you need a detector that does not rely on IgG spanning 25 nm by itself.
Why each enhancement medium exists
Think of every medium as an answer to zeta potential, antibody uptake rate, or antigen accessibility. Validated recipes sit in IV.C (Chapter 15). Principles live here.
- Medium What it does What you gain What you pay
- Saline (IS / RT / 37) No enhancer Detects IgM (ABO, many colds) Misses most IgG
22% albumin Modest zeta reduction; 37 °C incubation Older way to see some incomplete antibodies Slow; less sensitive than LISS/PEG
LISS Low ionic strength accelerates antibody association 10–15 min incubation; good sensitivity Potentiates cold autoantibodies ; technique-sensitive
PEG Excludes water, concentrating antibody Very sensitive, especially Kidd Do not read at 37 °C (nonspecific aggregation); wash hard before AHG; enhances warm autos
Enzymes (ficin, papain, bromelin) Cleave sialoglycoproteins, drop zeta , expose some epitopes Enhance Rh, Kidd, Lewis, I, P1, ABO Destroy M, N, S/s (variable), Fya/Fyb, Xga, Ch/Rg ; can make colds louder
AHG Anti-IgG (± anti-C3) bridges Fc of bound IgG Detects coating IgG that saline cannot show Requires adequate washes ; check cells after a negative
Enzymes do not “create” antibodies. They change the membrane. A panel that appears after ficin and was silent in LISS is often a Rh or Kidd antibody that liked the stripped cells. A panel that vanishes after ficin is in the destroyed list — start with Duffy or MNS, not Kell (Kell is enzyme-resistant).
Dosage is a testing principle, not a blood-group chapter. Some antibodies react more strongly with homozygous (double-dose) cells than with heterozygous cells. Kidd, Duffy, Rh (especially c, E), and MNS are the usual dosage systems. A heterozygous screen cell can miss a weak anti-Jka. That is why a history of delayed HTR plus a “negative” screen still makes you look at Kidd zygosity. Enhancement media can unmask dosage-weak reactions; they do not abolish the biology.
DAT versus IAT
Both use AHG. They differ in where the coating happened .
Direct antiglobulin test (DAT): patient red cells, already coated in vivo , are washed and mixed with AHG. Positive in HTR, HDFN, AIHA, and some drug reactions . You are not adding serum; the antibody is already on the cell.
Indirect antiglobulin test (IAT): you incubate serum or reagent antibody with red cells in vitro , wash, then add AHG. This is the antibody screen, antibody ID, AHG crossmatch, and AHG antigen type .
A positive DAT with a negative eluate and a negative screen is not “IAT failed.” It is a different question (often drug or nonspecific). Chapter 13 works the workup; the principle is in-vivo versus in-vitro coating .
Hemolysis is a positive result
Complement-binding antibody can lyse cells if the test system has intact complement (fresh serum , not EDTA plasma — Section 10.4). Hemolysis is a positive reaction , equal in interpretive weight to strong agglutination. Classic hemolysins: ABO , some Kidd , Lewis , Vel , P/PP1Pk , and some H (Bombay). Never discard a hemolyzed test tube as a bad draw if the control cells are intact and the hemolysis appeared after incubation.
Temperature is the first antibody-class clue
Phase Typical isotype Typical specificities Clinical bias
Immediate spin / room temp IgM ABO, Lewis, I, P1, M, N, Lua Usually insignificant if 37 °C-negative ( ABO excepted )
37 °C and/or AHG IgG Rh, Kell, Kidd, Duffy, Ss, Lub Significant until proven otherwise
Thermal amplitude is how far a cold antibody reacts toward 37 °C. Anti-I that reacts only at 4 °C is noise. Anti-I that reacts at 30–37 °C can destroy units (cold agglutinin disease). Warm IgG that also shows a cold tail is still worked up as a warm antibody. Temperature is a clue, not a substitute for a 37 °C / AHG panel.
Exam traps
Calling affinity and avidity synonyms. Affinity = one site; avidity = the molecule.
Ignoring prozone and reporting a false-negative high-titer antibody.
Reading a PEG tube at 37 °C and calling the sludge “4+.”
Using enzymes to “enhance everything.” They destroy Duffy and MNS .
Treating DAT and IAT as interchangeable rather than in-vivo versus in-vitro .
Throwing away hemolysis.
Assuming dosage never hides a Kidd antibody on a heterozygous screen cell.